Tag:
Relypsa
Latest Headlines
Latest Headlines
Hastings, McGirr to sit on Relypsa board
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
Q3 biotech venture investing makes a boisterous leap
The life sciences industry gained a blast of good news on the venture front today. The National Venture Capital Association and PricewaterhouseCoopers outlined a buoyant set of numbers for the...
Relypsa completes $80M round as it preps pivotal heart study
The money--which follows a $70 million round two years ago--will be used to put RLY5016 to the ultimate test as a treatment for hyperkalemia, a condition in which high levels of potassium threatens patients suffering from diabetes, heart failure, and kidney disease with a potentially lethal case of arrhythmia.
Relypsa reloads with $50M to support late-stage drug quest
Two years after an experienced team of biotech executives gathered a whopping $70 million venture round for Relypsa, the Santa Clara, CA-based developer is almost $50 million closer to another big round of financing, according to SEC documents.
Relypsa banks $70M Series B for pivotal trial work
Relypsa, the start-up biotech born out of Amgen's acquisition of Ilypsa, has rounded up a whopping $70 million for its Series B, bringing its venture haul to more than $100 million. Santa Clara,
